Feasibility of extension of platinum-free interval with weekly bolus topotecan and subsequent platinum retreatment outcomes in recurrent ovarian cancer (original) (raw)
Jemal A, Siegel R, Ward E et al (2008) Cancer Statistics, 2008. CA Cancer J Clin 58:71–96 ArticlePubMed Google Scholar
Armstrong DK (2002) Relapsed ovarian cancer: challenges and management strategies for a chronic disease. Oncologist 7:20–28 ArticleCASPubMed Google Scholar
Rose PG, Smrekar M, Haba P et al (2005) A phase I/II trial of weekly topotecan and carboplatin in potentially platinum-sensitive relapsed ovarian and peritoneal carcinoma. Gynecol Oncol 99:714–719 ArticleCASPubMed Google Scholar
Bhoola SM, Hoskins WJ (2006) Diagnosis and management of epithelial ovarian cancer. Obstet Gynecol 107:1399–1410 ArticlePubMed Google Scholar
Burger RA, Sill M, Monk BJ, Greer B, Sorosky J (2007) Phase II trial of Bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group study. J Clin Oncol 25:5165–5171 ArticleCASPubMed Google Scholar
Gordon AN, Fleagle JT, Guthrie D et al (2001) Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan. J Clin Oncol 19:3312–3322 CASPubMed Google Scholar
Gordon AN, Tonda M, Sun S et al (2004) Long-term survival advantage for women treated with pegylated liposomal doxorubicin compared with topotecan in a phase 3 randomized study of recurrent and refractory epithelial ovarian cancer. Gynecol Oncol 95:1–8 ArticleCASPubMed Google Scholar
Parmar M, Ledermann J, Colombo N et al (2003) Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial. Lancet 361:2099–2106 ArticleCASPubMed Google Scholar
Pfisterer J, Plante M, Vergote I et al (2006) Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG. J Clin Oncol 24:4699–4707 ArticleCASPubMed Google Scholar
ten Bokkel Huinink W, Gore M, Carmichael J et al (1997) Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer. J Clin Oncol 15:2183–2193 CASPubMed Google Scholar
Bookman MA (1999) Extending the platinum-free interval in recurrent ovarian cancer: the role of topotecan in second-line chemotherapy. Oncologist 4:87–94 CASPubMed Google Scholar
Horowitz NS, Hua J, Gibb RK et al (2004) The role of topotecan for extending the platinum-free interval in recurrent ovarian cancer: an in vitro model. Gynecol Oncol 94:67–73 ArticleCASPubMed Google Scholar
Cannistra SA (2002) Is there a “Best” choice of second-line agent in the treatment of recurrent, potentially platinum-sensitive ovarian cancer? J Clin Oncol 20:1158–1160 PubMed Google Scholar
Morris RT (2003) Weekly topotecan in the management of ovarian cancer. Gynecol Oncol 90:S34–S38 ArticleCASPubMed Google Scholar
Morris RT, Alvarez RD, Andrews S, Malone J, Bryant CS et al (2008) Topotecan weekly bolus chemotherapy for relapsed platinum-sensitive ovarian and peritoneal cancer. Gynecol Oncol 109:346–352 ArticleCASPubMed Google Scholar
McGuire WP, Blessing JA, Bookman MA et al (2000) Topotecan has substantial antitumor activity as first-line salvage therapy in platinum-sensitive epithelial ovarian carcinoma: A Gynecologic Oncology Group study. J Clin Oncol 18:1062–1067 CASPubMed Google Scholar
Bhoola SM, Coleman R, Herzog TJ, Morris RT, Bryant CS et al (2004) Retrospective analysis of weekly topotecan as salvage therapy in relapsed ovarian cancer. Gynecol Oncol 95:564–569 ArticleCASPubMed Google Scholar
O’Malley DM, Azodi M, Makkenchery A et al (2005) Weekly topotecan in heavily pretreated patients with recurrent epithelial ovarian carcinoma. Gynecol Oncol 98:242–248 ArticlePubMed Google Scholar
Safra T, Menczer J, Bernstein R et al (2007) Efficacy and toxicity of weekly topotecan in recurrent epithelial ovarian and primary peritoneal cancer. Gynecol Oncol 105:205–210 ArticleCASPubMed Google Scholar
Bookman MA, Malmstrom H, Bolis G et al (1998) Topotecan for the treatment of advanced epithelial ovarian cancer: an open-label phase II study in patients treated after prior chemotherapy that contained cisplatin or carboplatin and paclitaxel. J Clin Oncol 16:3345–3352 CASPubMed Google Scholar
Creemers GJ, Bolis G, Gore M, Scarfone G, Lacave AJ, Guastalla JP, Despax R, Favalli G, Kreinberg R, Van Belle S, Hudson I, Verweij J, ten Bokkel Huinink WW (1996) Topotecan, an active drug in the second-line treatment of epithelial ovarian cancer: results of a large European phase II study. J Clin Oncol 14:3056–3061 CASPubMed Google Scholar
Hoskins P, Eisenhauer E, Beare S et al (1998) Randomized phase II study of two schedules of topotecan in previously treated patients with ovarian cancer: a National Cancer Institute of Canada Clinical Trials Group study. J Clin Oncol 16:2233–2237 CASPubMed Google Scholar
Pignata S, Ferrandina G, Scarfone G et al (2006) Extending the platinum-free interval with a non-platinum therapy in platinum-sensitive recurrent ovarian cancer. Oncology 71:320–326 ArticleCASPubMed Google Scholar
Armstrong DK (2004) Topotecan dosing guidelines in ovarian cancer: reduction and management of hematologic toxicity. Oncologist 9:33–42 ArticleCASPubMed Google Scholar
Kavanagh J, Tresukosol D, Edwards C et al (1995) Carboplatin reintroduction after taxane in patients with platinum-refractory epithelial ovarian cancer. J Clin Oncol 13:1584–1588 CASPubMed Google Scholar
Dizon DS, Hensley ML, Poynor EA et al (2002) Retrospective analysis of carboplatin and paclitaxel as initial second-line therapy for recurrent epithelial ovarian carcinoma: application toward a dynamic disease state model of ovarian cancer. J Clin Oncol 20:1238–1247 ArticleCASPubMed Google Scholar
Penson RT, Seiden MV (2005) Topotecan: weighing in when there are many options. Oncologist 10:698–700 ArticleCASPubMed Google Scholar
Spriggs D (2003) Optimal sequencing in the treatment of recurrent ovarian cancer. Gynecol Oncol 90:S39–S44 ArticleCASPubMed Google Scholar
Leitao MM Jr, Hummer A, Dizon DS et al (2003) Platinum retreatment of platinum-resistant ovarian cancer after nonplatinum therapy. Gynecol Oncol 91:123–129 ArticleCASPubMed Google Scholar
See HT, Freedman RS, Kudelka AP, Burke TW et al (2005) Retrospective review: re-treatment of patients with ovarian cancer with carboplatin after platinum resistance. Int J Gynecol Cancer 15:209–216 ArticleCASPubMed Google Scholar
Gronlund B, Hogdall C, Christensen IJ et al (2004) Is stabilization of disease a useful indicator for survival in second-line treatment of ovarian carcinoma pre-treated with paclitaxel-platinum? Gynecol Oncol 94:409–415 ArticleCASPubMed Google Scholar
Alberts DS, Kiu PY, Wilczynski SP, Clouser MC, Lopez AM, Michelin DP, Lanzotti VJ, Markman M (2008) Randomized trial of pegylated liposomal doxorubicin (PLD) plus carboplatin versus carboplatin in platinum-sensitive (PS) patients with recurrent epithelial ovarian or peritoneal carcinoma after failure of initial platinum-based chemotherapy (Southwest Oncology Group Protocol S0200). Gynecol Oncol 107:90–94 Article Google Scholar
Sehouli J, Oskay-Oezcelik G, Stengel D, du Bois A, Markmann S, Loibl S, Wilke J, Nugent A, Belau A, Lichtenegger W (2007) Topotecan weekly versus routine 5-day schedule in patients with platinum-resistant ovarian cancer (TOWER): a randomized, two-stage phase-II study of the North-Eastern German Society of Gynaecological Oncology (NOGGO). J Clin Oncol 25:5526 Google Scholar
Pignata S, Perrone F, Morabito A, Gallo C Efficacy study of chemotherapy to treat ovarian cancer recurrence and to prolong the platinum free interval (MITO-8). ClinicalTrials.gov identifier: NCT00657878. http://clinicaltrials.gov/ct2/show/NCT0065787